SEARCH

SEARCH BY CITATION

References

  • 1
    Shiftman ML, Jeffers L, Hoofnagle JH, Tralka TS. The role of transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension and its complications: a conference sponsored by the National Digestive Diseases Advisory Board. Hepatology 1995; 22: 15911597.
  • 2
    Azoulay D, Castaing D, Dennison A, Martino W, Eyraud D, Bismuth H. Transjugular intrahepatic portosystemic shunt worsen the hyperdynamic state of the cirrhotic patient: preliminary report of a prospective study. Hepatology 1994; 19: 129132.
  • 3
    Quiroga J, Sangro B, Núnez M, Bilbao I, Longo J, García-Villarreal L, Zozaya JM, et al. Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters. Hepatology 1995; 21: 986994.
  • 4
    Rodríguez-Laíz JM, Banares R, Echenagusia A, Casado M, Camúnez F, Pérez-Roldán F, De Diego A, et al. Effects of transjugular intrahepatic portasystemic shunt (TIPS) on splanchnic and systemic hemodynamics, and hepatic function in patients with portal hypertension. Preliminary results. Dig Dis Sci 1995; 40: 21212127.
  • 5
    Gelman S, Aldrete JS, Halpern N. Hemodynamics during portacaval shunt surgery in humans. Anesth Analg 1982; 61: 185186.
  • 6
    Kravetz D, Arderiu MT, Bosch J, Fuster J, Visa J, Casamitjana R, Rodés J. Hyperglucagonemia and hyperkinetic circulation after portacaval shunt in the rat. Am J Physiol 1987; 252: G257G261.
  • 7
    Bandi JC, Fernández M, Bernadich C, García-Pagán JC, Bosch J, Rodés J. Hyperkynetic circulation and decreased sensitivity to vasoconstrictors following portacaval shunt in the rat. Effects of nitric oxide inhibition [Abstract];. Hepatol 1995; 23 (suppl 1): 112A.
  • 8
    Henderson JM, Millikan WJ, Wright-Bacon C, Kutner MH, Warren WD. Hemodynamic differences between alcoholic and nonalcoholic cirrhotics following distal splenorenal shunts: effect on survival? Ann Surg 1983; 198: 325334.
  • 9
    Lacy A, Navasa M, Gilabert R, Bru C, García-Pagán JC, García-Valdecasas JC, Grande L, et al. Long-term effects of distal splenorenal shunt on hepatic hemodynamics and liver function in patients with cirrhosis: importance of reversal of portal blood flow. Hepatology 1992; 15: 616622.
  • 10
    Sarfeh IJ, Ryping EB, Mason GR. A systematic appraisal of portacaval H-graft diameters. Clinical and hemodynamic perspectives. Ann Surg 1986; 204: 356363.
  • 11
    Ryping EB, Sarfeh IJ. Influence of portal hemodynamics on long-term survival of alcoholic cirrhotic patients after small-diameter portacaval H-grafts. Am J Surg 1988; 155: 152158.
  • 12
    Fernández-Rodríguez CM, Prieto J, Quiroga J, Zozaya JM, Andrade A, Núnez M, Sangro B, et al. Plasma levels of substance P in liver cirrhosis: relationship to the activation of vasopressors system and urinary sodium excretion. Hepatology 1995; 21: 3540.
  • 13
    Bosch J, Pizcueta P, Fernández M, Feu F, Cirera I, Luca A, García-Pagán JC. Hepatic, splanchnic and systemic hemodynamics abnormalities in portal hypertension. Clin Gastroenterol 1992; 6: 425436.
  • 14
    Benoit JN, Barrowman JA, Harper SL, Kviets PR, Granger DN. Role of humoral factors in the intestinal hyperemia associated with chronic portal hypertension. Am J Physiol 1984; 247: G486G493.
  • 15
    Benoit JN, Zimmermann B, Premen AJ, Go CLW, Granger DN. Role of glucagon in splanchnic hyperemia of chronic portal hypertension. Am J Physiol 1986; 251: G674G678.
  • 16
    Pizcueta MP, García-Pagán JC, Fernández M, Casamitjana R, Bosch J, Rodés J. Glucagon hinders the effects of somatostatin on portal hypertension. A study in rats with partial portal vein ligation. Gastroenterology 1991; 101: 17101715.
  • 17
    Pizcueta MP, Piqué JM, Bosch J, Whittle BJR, Moncada S. Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension. Br J Pharmacol 1992; 105: 184190.
  • 18
    Pizcueta MP, Piqué JM, Fernández M, Bosch J, Rodés J, Whitlle BJR, Moncada S. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology 1992; 103: 19091915.
  • 19
    García-Pagán JC, Fernández M, Bernadich C, Pizcueta MP, Piqué JM, Bosch J, Rodés J. Effects of continued nitric oxide inhibition on the portal hypertensive syndrome after portal vein stenosis in the rat. Am J Physiol 1994; 30: G984G990.
  • 20
    Bernadich C, Fernández M, Bandi JC, Bosch J, Rodés J. Mechanical pumping of portal blood to the liver: hemodynamic effects of a new experimental treatment for portal hypertension. J Hepatol 1996; 25: 98105.
  • 21
    Sikuler E, Kravetz D, Groszmann RJ. Evolution of portal hypertension and mechanism involved in its maintenance in a rat model. Am J Physiol 1985; 248: G618G625.
  • 22
    Pizcueta MP, DeLacy AM, Kravetz D, Bosch J, Rodés J. Propranolol decreases portal pressure without changing portal-collateral resistance in cirrhotic rats. Hepatology 1989; 10: 953957.
  • 23
    Osborn JW, Barber BJ, Quillen EW, Abram RJ, Copwley AW. Chronic measurement of cardiac output in unanesthetized rats using miniature thermocouples. Am J Physiol 1986; 251: H1365H1372.
  • 24
    Castro A, Jiménez W, Clària J, Ros J, Martínez JM, Bosch M, Arroyo V, et al. Impaired responsiveness to angiotensin II in experimental cirrhosis: role of nitric oxide. Hepatology 1993; 18: 367372.
  • 25
    Pizcueta MP, Casamitjana R, Bosch J, Rodés J. Decreased systemic vascular sensitivity to norepinephrine in portal hypertensive rats. Role of hyperglucagonism. Am J Physiol 1990; 258: G191G195.
  • 26
    Lee FY, Albillos A, Colombato A, Groszmann RJ. The role of nitric oxide in the vascular hyporesponsiveness to methoxamine in portal hypertensive rats. Hepatology 1992; 16: 10431048.
  • 27
    Clària J, Jiménez W, Ros J, Asbert M, Castro A, Arroyo V, Rivera F, et al. Pathogenesis of arterial hypotension in cirrhotic rats with ascites: role of endogenous nitric oxide. Hepatology 1992; 15: 343349.
  • 28
    Kana AJ, Strauss HC, Truskey GA, Cews AL, Grunfeld S, Malinski T. Shear-stress induces ATP-independent transient nitric oxide release from vascular endothelial cells, measured directly with a porphyrinic microsensor. Circ Res 1995; 77: 284293.
  • 29
    Gray DW, Marshall I. Human alpha-calcitonin gene-related peptide stimulates adenylate ciclase and guanylate ciclase and relaxes rat thoracic aorta by releasing nitric oxide. Br J Pharmacol 1992; 107: 691696.